New oncolytic virus platform GEEV® expresses a regulatory protein on its membrane to evade innate immune system, based on vaccinia virus whose safety and efficacy have been proven through clinical trials. SJ-600 series oncolytic virus, the representative GEEV® platform, maintains stable oncolytic activity when administered intravenously since GEEV® platform deactivates innate immune system. SJ-600 series oncolytic virus can act as a novel platform to enable systemic treatment, thus it will expand the target cancer profile to include deep-seated cancers and widespread metastatic cancers.